Phase I Study of the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 With Blocking of Autocrine Loops VEGFR1/2/3
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs LYN 00101 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Lynkcell
- 28 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2019 Planned End Date changed from 2 Jul 2019 to 1 Feb 2020.
- 02 Apr 2019 Planned primary completion date changed from 10 Apr 2019 to 1 Nov 2019.